Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 508

1.

Drug safety. Gaps in the safety net.

Couzin J.

Science. 2005 Jan 14;307(5707):196-8. No abstract available.

PMID:
15653480
3.

Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.

Shea LL, Hanson A, Guglielmetti TM, Levy K.

Food Drug Law J. 2007;62(3):445-72. No abstract available.

PMID:
17915388
4.

Federal Drug Administration authority and the emergency nurse: implications for patient safety.

Hackenschmidt A.

J Emerg Nurs. 2006 Oct;32(5):449-50. Epub 2006 Aug 7. No abstract available.

PMID:
16997042
5.

Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Lexchin J.

CMAJ. 2005 Mar 15;172(6):765-7. No abstract available.

6.

FDA attempting to overcome major roadblocks in monitoring drug safety.

Zielinski SL.

J Natl Cancer Inst. 2005 Jun 15;97(12):872-3. No abstract available.

7.

The role of databases in drug postmarketing surveillance.

Rodriguez EM, Staffa JA, Graham DJ.

Pharmacoepidemiol Drug Saf. 2001 Aug-Sep;10(5):407-10.

PMID:
11802586
9.

PDUFA reauthorization--drug safety's golden moment of opportunity?

Hennessy S, Strom BL.

N Engl J Med. 2007 Apr 26;356(17):1703-4. Epub 2007 Apr 13. No abstract available.

10.

Paying for drug approvals--who's using whom?

Avorn J.

N Engl J Med. 2007 Apr 26;356(17):1697-700. Epub 2007 Apr 13. No abstract available.

11.

Vioxx's history and the need for better procedures and better testing.

Gilhooley M.

Seton Hall Law Rev. 2007;37(4):941-68. No abstract available.

PMID:
18363218
12.

Safety in numbers--monitoring risk in approved drugs.

Okie S.

N Engl J Med. 2005 Mar 24;352(12):1173-6. No abstract available.

PMID:
15788493
13.

The marketplace can't give us the drug safety data we need.

Avorn J.

MedGenMed. 2007 Feb 9;9(1):29. No abstract available.

14.

Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference.

Crawford LM.

Food Drug Law J. 2005;60(2):99-102. No abstract available.

PMID:
16097087
15.

Postmarketing surveillance and reporting of adverse drug events.

Baer RK.

S D J Med. 2004 Jan;57(1):13-4. Review. No abstract available.

PMID:
14964975
16.

FDA guidance document on monitoring delayed adverse events a good first start.

Williams DA.

Mol Ther. 2005 Dec;12(6):991-2. Epub 2005 Nov 3. No abstract available.

PMID:
16271514
17.

The prescription drug user fee act: active postmarketing drug surveillance and safety.

Lyles A.

Clin Ther. 2002 May;24(5):800-2. No abstract available.

PMID:
12075947
18.

Reform of drug regulation--beyond an independent drug-safety board.

Ray WA, Stein CM.

N Engl J Med. 2006 Jan 12;354(2):194-201. No abstract available.

PMID:
16407517
19.

Opening Pandora's pillbox: using modern information tools to improve drug safety.

Gottlieb S.

Health Aff (Millwood). 2005 Jul-Aug;24(4):938-48.

20.

Drug safety reform at the FDA--pendulum swing or systematic improvement?

McClellan M.

N Engl J Med. 2007 Apr 26;356(17):1700-2. Epub 2007 Apr 13. No abstract available.

Items per page

Supplemental Content

Write to the Help Desk